Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Income Tax Expense
Income taxes recognized for the period, including current and deferred tax.
Citius Oncology, Inc.NASDAQ: CTOR
Income Tax Expense · Q2 FY2026 · quarter ended Mar 2026
Income tax expense turns negative
Q2 FY2026 income tax expense was -$231.21K, compared with $264.24K a year earlier. Trailing-twelve-month income tax expense was $561.51K. Over 3 fiscal years it compounded at -2.8% a year.
Context
- Income tax expense increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly income tax expense holds near -$231.21K or moves back toward the trailing-twelve-month quarterly average of $140.38K.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Tax Expense history
USD · from the income statement
- Latest · FY2025
- 1.06M USD
- Year-over-year change
- +83.5%
- 3-year CAGR
- -2.8%
| Period | Period end | Income Tax Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 1.06M | +83.5% |
| FY2024 | 2024-09-30 | 576K | +0.0% |
| FY2023 | 2023-09-30 | 576K | -50.0% |
| FY2022 | 2022-09-30 | 1.15M | — |
Income Tax Expense vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's LTM Mar 2026 income tax expense of $561.51K is the 2nd highest of the 10 companies compared; the peer median is $800.
- Its year-over-year change of -31.2% is the 2nd highest of 3, against a peer median of +1201.8%.
- Income tax expense amounts to 10.0% of revenue for CTOR, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.41M | — | — | — | |
CTORCitius Oncology, Inc. | LTM Mar 2026 | $561.51K | -31.2% | -2.8% | 10.0% |
| LTM Mar 2026 | $261K | — | — | 0.5% | |
| LTM Mar 2026 | $24K | +2499.9% | +86.6% | 0.1% | |
| LTM Mar 2026 | $23K | -96.4% | -1.2% | 0.0% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $800 | — | — | — |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding CTOR) | $800 | +1201.8% | +42.7% | 0.0% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 6.86M | 4.24M | 4.93M | 6.42M |
| Selling, General & Admin | 2.86M | 7.88M | 15.65M | 17.1M |
| Operating Expenses | 9.71M | 12.12M | 20.57M | 23.52M |
| Depreciation & Amortization | 9.71M | 0 | 0 | 0 |
| EBITDA | 0 | (12.12M) | (20.57M) | (23.49M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (9.71M) | (12.12M) | (20.57M) | (23.52M) |
| Operating Margin | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 36.37K |
| Interest Expense | 0 | 0 | 0 | 218.03K |
| Other Income / Expenses | 0 | 0 | 0 | (181.66K) |
| Income Before Tax | (9.71M) | (12.12M) | (20.57M) | (23.7M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 1.15M | 576K | 576K | 1.06M |
| Net Income | (10.87M) | (12.7M) | (21.15M) | (24.76M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.08) | (0.19) | (0.30) | (0.34) |
| EPS (Diluted) | (0.08) | (0.19) | (0.30) | (0.34) |
| Weighted Avg Shares | 90.16M | 89.48M | 71.55M | 73.27M |
| Weighted Avg Shares (Diluted) | 90.16M | 89.48M | 71.55M | 73.27M |
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.